By Application
Hot products 
-
Rat Anti-C5AR1 Recombinant Antibody (8D6) (CBMAB-C9139-LY)
-
Mouse Anti-ADIPOR2 Recombinant Antibody (V2-179983) (CBMAB-A1369-YC)
-
Rabbit Anti-Acetyl-Histone H4 (Lys16) Recombinant Antibody (V2-623415) (CBMAB-CP1021-LY)
-
Mouse Anti-ENO1 Recombinant Antibody (CBYC-A950) (CBMAB-A4388-YC)
-
Mouse Anti-BrdU Recombinant Antibody (IIB5) (CBMAB-1038CQ)
-
Mouse Anti-HTLV-1 gp46 Recombinant Antibody (CBMW-H1006) (CBMAB-V208-1154-FY)
-
Mouse Anti-ADIPOR1 Recombinant Antibody (V2-179982) (CBMAB-A1368-YC)
-
Mouse Anti-FLI1 Recombinant Antibody (CBXF-0733) (CBMAB-F0435-CQ)
-
Mouse Anti-APOH Recombinant Antibody (4D9A4) (CBMAB-A3249-YC)
-
Mouse Anti-BHMT Recombinant Antibody (CBYY-0547) (CBMAB-0550-YY)
-
Mouse Anti-GPR34 Recombinant Antibody (CBFYH-0457) (CBMAB-H1331-FY)
-
Mouse Anti-DDC Recombinant Antibody (8E8) (CBMAB-0992-YC)
-
Mouse Anti-ACTN4 Recombinant Antibody (V2-6075) (CBMAB-0020CQ)
-
Mouse Anti-BRCA2 Recombinant Antibody (CBYY-1728) (CBMAB-2077-YY)
-
Mouse Anti-BCL6 Recombinant Antibody (CBYY-0435) (CBMAB-0437-YY)
-
Mouse Anti-GP1BA Recombinant Antibody (6D1) (CBMAB-0271-CN)
-
Mouse Anti-AKT1 (Phosphorylated S473) Recombinant Antibody (V2-505430) (PTM-CBMAB-0067LY)
-
Mouse Anti-CD19 Recombinant Antibody (CBXC-1224) (CBMAB-C1491-CQ)
-
Rabbit Anti-AKT3 Recombinant Antibody (V2-12567) (CBMAB-1057-CN)
-
Mouse Anti-ACO2 Recombinant Antibody (V2-179329) (CBMAB-A0627-YC)
Endometrial Cancer
Fig.1 Endometrial cancer
Endometrial cancer is a cancer originating from the endometrium, which is the lining of the womb and uterus. The first sign is most abnormal vaginal bleeding but not associated with menstrual periods. Other symptoms include pain with urination, pelvic pain or sexual intercourse. Endometrial cancer occurs overwhelmingly after menopause. About 40% of cases are related to obesity. Besides it is also associated with diabetes, excessive estrogen exposure and high blood pressure. Hereditary causes contribution to 2–10% of the endometrial cancer cases. The most common type of endometrial cancer is endometrioid carcinoma, which making up more than 80% of cases. The five-year survival rate for endometrial adenocarcinoma following appropriate treatment is around 80%. Prognostic markers, like Serum HE4 have been studied recently.
Loading...
Compare
